{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-22-000007","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.561671+00:00","generated_at":"2026-06-27T03:49:42.001405+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vallon Pharmaceuticals adds Meenu Karson to board; Ofir Levi steps down from committees","bullets":["Board expanded from 5 to 6 directors; Meenu Karson appointed as independent director.","Ofir Levi resigned from Audit and Nominating & Corporate Governance committees but remains Board Chair.","Karson appointed to Audit Committee and as Chair of Nominating & Corporate Governance Committee.","Karson is former President/CEO of Proteostasis Therapeutics, raised $300M+ and led IPO."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-22-000007","json":"https://secwatch.observer/filing/0001824293-22-000007.json","markdown":"https://secwatch.observer/filing/0001824293-22-000007.md","text":"https://secwatch.observer/filing/0001824293-22-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000007/0001824293-22-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000007/ck00018242493-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:49:42.001405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be17321657","claim":"Meenu Karson was appointed as director at GRI Bio, Inc..","evidence_excerpt":"increased the size of the Board from five directors to six directors and appointed Meenu Karson to serve as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000007/0001824293-22-000007-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}